lapatinib + letrozole

Lapatinib + letrozole is a combination therapy used for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. Lapatinib is a small molecule tyrosine kinase inhibitor that targets both HER1/EGFR and HER2 receptors, inhibiting intracellular signaling pathways involved in tumor cell proliferation and survival. Letrozole is an aromatase inhibitor that reduces estrogen production, thereby suppressing the growth of hormone-sensitive breast cancer cells. The combination has demonstrated significantly improved progression-free survival, objective response rate, and clinical benefit rate compared to letrozole alone in this patient population[1][5][6].

Brand names

FemaraTykerb

Other names

lapatinib and letrozoleletrozole plus lapatinib